Meeting Spolight: 2021 International Kidney Cancer Symposium

Proactive management of treatment-emergent adverse events, including treatment interruption, may be crucial for patients with renal cell carcinoma receiving lenvatinib in combination with pembrolizumab, according to the CLEAR study investigators.

Despite advanced in the field of renal cell carcinoma, most patients still die of the disease and more options and new targets are needed, says Moshe C. Ornstein, MD, MA.